TL;DR
- Pineapple Financial, listed on the NYSE American, has become the first public company to establish a $100 million Injective treasury, aiming for 12% annual staking returns.
- The move coincides with growing institutional interest in Injective, including an SEC review of a staked INJ ETF filed by Canary Capital.
- Following the announcement, INJ surged 7% to $13.2, with analysts forecasting potential resistance near $15.5 if bullish momentum holds.
Pineapple Financial has announced the creation of a $100 million Injective (INJ) treasury, making it the first publicly traded corporation to secure a large-scale position in the token. Listed under the ticker PAPL on the NYSE American, the fintech firm raised the funds through a private placement and confirmed that the treasury will be primarily staked to capture yields of approximately 12% per year.
According to Injective co-founder Eric Chen, this development signals a growing recognition of Injective as a leading blockchain ecosystem for institutions. He described the fund launch as a milestone that highlights Injective’s scalability, efficiency, and expanding use cases across decentralized finance.
Institutional Adoption Expands Across Multiple Networks
The announcement arrives amid accelerating corporate adoption of digital asset treasuries in the United States. Strategy, formerly MicroStrategy, has been at the forefront since 2020, when it began accumulating Bitcoin. As of 2025, its 636,505 BTC position is valued at $71 billion, providing more than $25 billion in unrealized gains.
Other firms have also followed this path. Sharplink Gaming disclosed holdings of nearly 800,000 ETH, while Bitmine, led by Tom Lee, increased its Ethereum portfolio to 1.8 million ETH valued near $2 billion. In August 2025, CEA Industries subsidiary BNB Network Company purchased 200,000 BNB tokens worth $160 million, becoming the largest corporate holder of Binance Coin at the time. Meanwhile, Sol Strategies in Canada has directed over CAD $1 billion into Solana allocations.
Injective Price Outlook Shows Signs Of Strength
Following Pineapple’s announcement, INJ rose from $12.0 to an intraday high of $13.2 before settling near $12.8. Market indicators suggest easing sell pressure after a weak close to August, when the token dropped 14% in just three sessions. Analysts note that a move above $13.8 could unlock further gains toward $15.5, with potential to revisit $16 if bullish momentum extends.
On the downside, a break below $12.0 could expose INJ to further correction, with $11.5 standing as the next key support. For now, traders are closely watching whether institutional inflows and regulatory developments will continue to fuel Injective’s upward trajectory.
